Get the Stockscreener App
11.57
5.47%
0.60
After Hours:
11.63
0.06
+0.52%
Novocure Ltd stock is traded at $11.57, with a volume of 4.07M.
It is up +5.47% in the last 24 hours and down -35.00% over the past month.
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
See More
Previous Close:
$10.97
Open:
$11.42
24h Volume:
4.07M
Relative Volume:
2.82
Market Cap:
$1.29B
Revenue:
$577.74M
Net Income/Loss:
$-149.78M
P/E Ratio:
-8.2643
EPS:
-1.4
Net Cash Flow:
$-78.21M
1W Performance:
-7.74%
1M Performance:
-35.00%
6M Performance:
-52.81%
1Y Performance:
-49.19%
1-Day Range:
$11.30
$12.38
1-Week Range:
$10.91
$12.73
52-Week Range:
$10.91
$34.13
Novocure Ltd Stock (NVCR) Company Profile
Name
Novocure Ltd
Sector
Industry
Phone
44 (0)15 3475 6700
Address
NO. 4 THE FORUM, ST. HELIER
Compare NVCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
11.57 | 1.23B | 577.74M | -149.78M | -78.21M | -1.40 |
|
ABT
Abbott Laboratories
|
126.19 | 223.66B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
104.92 | 157.95B | 18.49B | 2.51B | 2.72B | 1.68 |
|
SYK
Stryker Corp
|
392.73 | 153.02B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
90.24 | 117.42B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
79.31 | 47.61B | 5.69B | 4.15B | 623.10M | 6.95 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Dec-02-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-16-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Aug-28-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-08-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-04-23 | Initiated | SVB Securities | Outperform |
| Jul-31-23 | Upgrade | Evercore ISI | Underperform → In-line |
| Jun-07-23 | Upgrade | Wedbush | Underperform → Neutral |
| May-16-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-06-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-05-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-29-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-24-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-05-22 | Downgrade | Evercore ISI | In-line → Underperform |
| May-16-22 | Initiated | H.C. Wainwright | Buy |
| Feb-08-22 | Initiated | Loop Capital | Buy |
| Feb-02-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| Jan-03-22 | Upgrade | Evercore ISI | Underperform → In-line |
| Jul-01-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-14-21 | Downgrade | Wedbush | Neutral → Underperform |
| Jan-25-21 | Reiterated | Piper Sandler | Overweight |
| Sep-23-20 | Initiated | Northland Capital | Outperform |
| Sep-18-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-17-20 | Downgrade | Truist | Buy → Hold |
| Jun-01-20 | Resumed | Oppenheimer | Perform |
| May-01-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-09-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Mar-05-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-29-19 | Upgrade | SunTrust | Hold → Buy |
| Jul-26-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-19 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-20-19 | Initiated | SunTrust | Hold |
| Nov-02-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jul-16-18 | Initiated | Evercore ISI | Outperform |
| Apr-18-18 | Reiterated | Mizuho | Buy |
| Feb-23-18 | Reiterated | Mizuho | Buy |
| May-24-17 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Jul-29-16 | Reiterated | Wedbush | Outperform |
| Jan-19-16 | Initiated | Barclays | Underweight |
| Dec-02-15 | Initiated | Deutsche Bank | Hold |
View All
Novocure Ltd Stock (NVCR) Latest News
NovoCure: Cash Burn, A Costly Launch, And A Maturing Business Signal More Pain Ahead - Seeking Alpha
Will NovoCure Limited stock benefit from AI tech trendsWeekly Entry Signal Based Forecast Tool - Newser
Multi asset correlation models including NovoCure LimitedFree Low Risk Buy Zone Opportunity Watch - Newser
Short interest data insights for NovoCure LimitedMachine Learning Stock Price Forecast Tool - Newser
Why NovoCure Stock Is Cratering Today - Mitrade
NovoCure Limited (NASDAQ:NVCR) Q2 2025 Earnings Call Transcript - Insider Monkey
Does NovoCure Limited show high probability of reboundSafe Entry Strategy with High Win Rate - Newser
Novocure’s Earnings Call: Clinical Successes & Cautious Optimism - TipRanks
What are NovoCure Limited company’s key revenue driversDiscover undervalued stocks before they soar - jammulinksnews.com
Top 3 Health Care Stocks That May Explode In July - Benzinga
How strong is NovoCure Limited company’s balance sheetUnrivaled growth potential - jammulinksnews.com
Wells Fargo & Company Reaffirms Equal Weight Rating for NovoCure (NASDAQ:NVCR) - Defense World
NovoCure Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
NovoCure: Q2 Earnings Snapshot - Norwalk Hour
NovoCure Limited 2025 Q2ResultsEarnings Call Presentation (NASDAQ:NVCR) - Seeking Alpha
Bank of New York Mellon Corp Grows Stake in NovoCure Limited (NASDAQ:NVCR) - Defense World
Wells Fargo Downgrades NovoCure (NVCR) with Significant Price Ta - GuruFocus
NovoCure Limited Stock Analysis and ForecastBreakneck growth rates - Autocar Professional
NovoCure Ltd (NVCR) Q2 2025 Earnings Call Highlights: Revenue Gr - GuruFocus
NovoCure Ltd (NVCR) Q2 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges By GuruFocus - Investing.com Canada
Decoding NovoCure Ltd (NVCR): A Strategic SWOT Insight - GuruFocus
Novocure Ltd. Reports Q2 2025 Financial Results - TipRanks
Novocure Beat Revenue Expectations As Patient Numbers Grew - Finimize
How NovoCure Limited stock performs during market volatilityTargeted 200 Percent Gain - Newser
NovoCure Q2 Revenue Jumps 6 Percent - AOL.com
Small U.S. Stocks Decrease; Novocure Takes Biggest Hit - 富途牛牛
NovoCure Limited (NASDAQ:NVCR) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
NovoCure Ltd (NVCR) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com
Novocure stock hits 52-week low at 14.17 USD By Investing.com - Investing.com Canada
Novocure stock hits 52-week low at 14.17 USD - Investing.com Australia
Novocure Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
Novocure: Steady Ahead of Key Milestones - The Motley Fool
NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
NovoCure Ltd Q2 2025 Earnings: EPS Loss of $0.36 Beats Estimates - GuruFocus
Novocure Ltd earnings beat by $0.02, revenue topped estimates - Investing.com South Africa
NovoCure Ltd SEC 10-Q Report - TradingView
Novocure Reports Second Quarter 2025 Financial Results - Stock Titan
What drives NovoCure Limited stock priceSuperior investment outcomes - jammulinksnews.com
What analysts say about NovoCure Limited stockBreakthrough wealth creation - Autocar Professional
Is NovoCure Limited a good long term investmentOutstanding stock performance - jammulinksnews.com
M&T Bank Corp Sells 1,750 Shares of NovoCure Limited (NASDAQ:NVCR) - Defense World
Novocure Ltd Stock (NVCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):